NKX019 + Fludarabine + Cyclophosphamide

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Sclerosis

Conditions

Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Trial Timeline

Nov 4, 2024 → Oct 1, 2028

NCT ID

NCT06733935

About NKX019 + Fludarabine + Cyclophosphamide

NKX019 + Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Nkarta for Systemic Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06733935. Target conditions include Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Sclerosis were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06733935	Phase 1/2	Recruiting	Nov 4, 2024	Oct 1, 2028	Systemic Sclerosis

Competing Products

20 competing products in Systemic Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29